Cargando…

Current and future use of nucleo(s)tide prodrugs in the treatment of hepatitis C virus infection

This review describes the current state of discovery of past most important nucleoside and nucleotide prodrugs in the treatment of hepatitis C virus infection as well as future potential drugs currently in discovery or clinical evaluation. I highlight first generation landmark prodrug compounds whic...

Descripción completa

Detalles Bibliográficos
Autor principal:	Dousson, Cyril B
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2018
Materias:	SI: Advances in Antiviral Nucleoside Analogs and Their Prodrugs
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5890546/ https://www.ncbi.nlm.nih.gov/pubmed/29463095 http://dx.doi.org/10.1177/2040206618756430

Ejemplares similares

Nucleoside analogs as a rich source of antiviral agents active against arthropod-borne flaviviruses
por: Eyer, Luděk, et al.
Publicado: (2018)

Flexibility—Not just for yoga anymore!
por: Seley-Radtke, Katherine
Publicado: (2018)

Safety, Pharmacokinetics, and Antiviral Activity of AT-527, a Novel Purine Nucleotide Prodrug, in Hepatitis C Virus-Infected Subjects with or without Cirrhosis
por: Berliba, Elina, et al.
Publicado: (2019)

Nucleotide Prodrug Containing a Nonproteinogenic Amino Acid To Improve Oral Delivery of a Hepatitis C Virus Treatment
por: Feng, Joy Y., et al.
Publicado: (2018)

Pharmacokinetics of a Long-Acting Nanoformulated Dolutegravir Prodrug in Rhesus Macaques
por: McMillan, JoEllyn, et al.
Publicado: (2017)

Rethinking Remdesivir: Synthesis, Antiviral Activity, and Pharmacokinetics of Oral Lipid Prodrugs
por: Schooley, Robert T., et al.
Publicado: (2021)

Pharmacokinetics of Temsavir, the Active Moiety of the HIV-1 Attachment Inhibitor Prodrug, Fostemsavir, Coadministered with Cobicistat, Etravirine, Darunavir/Cobicistat, or Darunavir/Ritonavir with or without Etravirine in Healthy Participants
por: Moore, Katy, et al.
Publicado: (2022)

Stopping nucleos(t)ide analogue treatment in Caucasian hepatitis B patients after HBeAg seroconversion is associated with high relapse rates and fatal outcomes
por: Van Hees, S., et al.
Publicado: (2018)

Role of Mitochondrial RNA Polymerase in the Toxicity of Nucleotide Inhibitors of Hepatitis C Virus
por: Feng, Joy Y., et al.
Publicado: (2016)

Geneticin Stabilizes the Open Conformation of the 5′ Region of Hepatitis C Virus RNA and Inhibits Viral Replication
por: Ariza-Mateos, Ascensión, et al.
Publicado: (2016)

MK-571, a Cysteinyl Leukotriene Receptor 1 Antagonist, Inhibits Hepatitis C Virus Replication
por: Ruiz, Isaac, et al.
Publicado: (2020)

Integrated Resistance Analysis of CERTAIN-1 and CERTAIN-2 Studies in Hepatitis C Virus-Infected Patients Receiving Glecaprevir and Pibrentasvir in Japan
por: Krishnan, Preethi, et al.
Publicado: (2018)

Evaluation of AT-752, a Double Prodrug of a Guanosine Nucleotide Analog with In Vitro and In Vivo Activity against Dengue and Other Flaviviruses
por: Good, Steven S., et al.
Publicado: (2021)

Potent Antiviral Activities of the Direct-Acting Antivirals ABT-493 and ABT-530 with Three-Day Monotherapy for Hepatitis C Virus Genotype 1 Infection
por: Lawitz, Eric J., et al.
Publicado: (2016)

Pooled Resistance Analysis in Patients with Hepatitis C Virus Genotype 1 to 6 Infection Treated with Glecaprevir-Pibrentasvir in Phase 2 and 3 Clinical Trials
por: Krishnan, Preethi, et al.
Publicado: (2018)

On the road to C(4) rice: advances and perspectives
por: Ermakova, Maria, et al.
Publicado: (2019)

Analysis of Hepatitis C Virus Genotype 1b Resistance Variants in Japanese Patients Treated with Paritaprevir-Ritonavir and Ombitasvir
por: Krishnan, Preethi, et al.
Publicado: (2016)

Hepatitis C Virus Genotype 4 Resistance and Subtype Demographic Characterization of Patients Treated with Ombitasvir plus Paritaprevir/Ritonavir
por: Schnell, Gretja, et al.
Publicado: (2015)

In Vitro Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS5A Inhibitor Pibrentasvir
por: Ng, Teresa I., et al.
Publicado: (2017)

SILEN-C3, a Phase 2 Randomized Trial with Faldaprevir plus Pegylated Interferon α-2a and Ribavirin in Treatment-Naive Hepatitis C Virus Genotype 1-Infected Patients
por: Dieterich, Douglas, et al.
Publicado: (2014)

Hepatitis C Virus Protease Inhibitors Show Differential Efficacy and Interactions with Remdesivir for Treatment of SARS-CoV-2 In Vitro
por: Gammeltoft, Karen A., et al.
Publicado: (2021)

Characterization of a Novel Capsid Assembly Modulator for the Treatment of Chronic Hepatitis B Virus Infection
por: Burdette, Dara, et al.
Publicado: (2022)

Resistance Analysis of Baseline and Treatment-Emergent Variants in Hepatitis C Virus Genotype 1 in the AVIATOR Study with Paritaprevir-Ritonavir, Ombitasvir, and Dasabuvir
por: Krishnan, Preethi, et al.
Publicado: (2015)

In Vitro Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS3/4A Protease Inhibitor Glecaprevir
por: Ng, Teresa I., et al.
Publicado: (2017)

Characterization of the Anti-Hepatitis C Virus Activity of New Nonpeptidic Small-Molecule Cyclophilin Inhibitors with the Potential for Broad Anti-Flaviviridae Activity
por: Nevers, Quentin, et al.
Publicado: (2018)

AT-527, a Double Prodrug of a Guanosine Nucleotide Analog, Is a Potent Inhibitor of SARS-CoV-2 In Vitro and a Promising Oral Antiviral for Treatment of COVID-19
por: Good, Steven S., et al.
Publicado: (2021)

PTC725, an NS4B-Targeting Compound, Inhibits a Hepatitis C Virus Genotype 3 Replicon, as Predicted by Genome Sequence Analysis and Determined Experimentally
por: Graci, Jason D., et al.
Publicado: (2016)

Preclinical Profile and Characterization of the Hepatitis B Virus Core Protein Inhibitor ABI-H0731
por: Huang, Qi, et al.
Publicado: (2020)

Preclinical Characterization of NVR 3-778, a First-in-Class Capsid Assembly Modulator against Hepatitis B Virus
por: Lam, Angela M., et al.
Publicado: (2018)

ATI-2173, a Novel Liver-Targeted Non-Chain-Terminating Nucleotide for Hepatitis B Virus Cure Regimens
por: Squires, Katherine E., et al.
Publicado: (2020)

Hepatitis B Virus Capsid Assembly Modulators, but Not Nucleoside Analogs, Inhibit the Production of Extracellular Pregenomic RNA and Spliced RNA Variants
por: Lam, Angela M., et al.
Publicado: (2017)

Overview of antiviral medications used in ophthalmology
por: Hoffman, Jeremy
Publicado: (2020)

Virus-Like Particles Containing the E2 Core Domain of Hepatitis C Virus Generate Broadly Neutralizing Antibodies in Guinea Pigs
por: McGregor, Joey, et al.
Publicado: (2022)

Photosynthesis in the fleeting shadows: an overlooked opportunity for increasing crop productivity?
por: Wang, Yu, et al.
Publicado: (2020)

Photosynthesis in non‐foliar tissues: implications for yield
por: Simkin, Andrew J., et al.
Publicado: (2020)

The influence of stomatal morphology and distribution on photosynthetic gas exchange
por: Harrison, Emily L., et al.
Publicado: (2019)

Cellular perspectives for improving mesophyll conductance
por: Lundgren, Marjorie R., et al.
Publicado: (2020)

Role of the E2 Hypervariable Region (HVR1) in the Immunogenicity of a Recombinant Hepatitis C Virus Vaccine
por: Law, John L. M., et al.
Publicado: (2018)

Antigenicity and Immunogenicity of Differentially Glycosylated Hepatitis C Virus E2 Envelope Proteins Expressed in Mammalian and Insect Cells
por: Urbanowicz, Richard A., et al.
Publicado: (2019)

Screening of Natural Extracts for Inhibitors against Japanese Encephalitis Virus Infection
por: Guo, Jiao, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_los4pbddoclg2h99b34k8t4him